Working to deliver stockholder value

Visit these pages to stay apprised of our latest press releases, stock information, regulatory filings and upcoming scientific and corporate presentations.
CORPORATE PROFILE
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer.
Download Documentation  2010 Annual Report
Download Documentation  Corporate Fact Sheet
INVESTOR CONTACT
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: contact@seagen.com

STOCK QUOTE
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$19.61
Change (%) Stock is Up 1.11 (6.00%)
Volume3,216,252
Data as of 01/27/12 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
RECENT NEWSMore >
DateTitle 
01/26/12Seattle Genetics Announces Data from ADCETRIS™ in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
-Interim Data Demonstrate 65 Percent Response Rate in Patients with Relapsed CTCL- -Two Case Studies Provide First Report of Activity and Tolerability in PTCL-NOS Patients- SAN FRANCISCO--(BUSINESS WIRE)--Jan. 26, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lympho... 
Printer Friendly Version
01/26/12Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas
-Phase III Trial Planned in Front-line Mature T-Cell Lymphomas- SAN FRANCISCO--(BUSINESS WIRE)--Jan. 26, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company today announced interim results from 32 patients treated to date in a phase I clinical trial of ADCETRIS (brentuximab vedotin) administered in combination with or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic la... 
Printer Friendly Version
01/13/12Seattle Genetics Announces Updates to ADCETRIS™ Prescribing Information
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updates to the U.S. Prescribing Information (PI) for ADCETRIS™ (brentuximab vedotin). The revised PI will include the following updated information: A boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving ADCETRIS. ... 
Printer Friendly Version
01/04/12Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 4, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2012 at 10:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at http://www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattle Genetics is ... 
Printer Friendly Version
12/13/11Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
- Phase III Front-line Trial Planned in Advanced Stage Hodgkin Lymphoma Patients - SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2011-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced interim results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma patients. The dat... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Privacy Policy  |  Legal Notice